Share ownership Harmony Biosciences Holdings, Inc.

HRMY

US4131971040

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:46:31 2025-12-11 am EST			5-day change	1st Jan Change
39.44 ^USD	+0.42%		+2.69%	+14.15%

Dec. 08	Harmony Biosciences Holdings, Inc. Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome	CI
Dec. 01	Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating	MT

Share class: Harmony Biosciences Holdings, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	57,031,297	38,573,136 ( 67.64 %)	0	67.64 %

Major shareholders: Harmony Biosciences Holdings, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 11.16 %	6,425,605	11.16 %	227 M $
Marshman Fund Trust Ii 10.51 %	6,051,120	10.51 %	214 M $
Vanguard Fiduciary Trust Co. 8.85 %	5,097,176	8.85 %	180 M $
Fidelity Management & Research Co. LLC 6.679 %	3,846,972	6.679 %	136 M $
HBM Partners AG (Investment Management) 3.729 %	2,147,943	3.729 %	76 M $
American Century Cos., Inc. 2.899 %	1,669,565	2.899 %	59 M $
STATE STREET CORPORATION 2.871 %	1,653,604	2.871 %	58 M $
DFA Australia Ltd. 2.811 %	1,618,870	2.811 %	57 M $
LSV Asset Management 2.769 %	1,594,893	2.769 %	56 M $
Arrowstreet Capital LP 2.249 %	1,295,381	2.249 %	46 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	73.89%
Other	19.98%
State Street Corp.	2.87%
Individuals	1.42%
Schweizerische Nationalbank	0.14%
Governments	0.05%
Manulife Financial Corp.	0.04%
Danske Bank A/S	0.03%
Skandinaviska Enskilda Banken AB	0.03%
SEI Investments Co.	0.02%
Oakworth Capital, Inc.	0.02%
Hancock Whitney Corp.	0.02%
Unknown	1.49%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	83.37%
Switzerland	4.31%
Australia	2.81%
United Kingdom	2.5%
Individuals	1.42%
Canada	1.17%
Germany	0.89%
Ireland	0.8%
Sweden	0.33%
France	0.2%
Hong Kong	0.12%
Singapore	0.11%
Puerto Rico	0.1%
Netherlands	0.08%
Cayman Islands	0.08%
Israel	0.06%
Norway	0.06%
Denmark	0.03%
Austria	0.02%
Finland	0.02%
China	0.02%
Spain	0.01%

Based on 1000 largest holdings

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Employees

268

Sector

Pharmaceuticals

Calendar

Mar. 02 - Q4 2025 Earnings Release (Projected)

More about the company